Pharmacogenomic Testing to Inform Prescribing in Patients with Behavioral and Psychiatric Symptoms of Dementia (BPSD): Results from Two Small, Randomized, Controlled Trials

Behavioral and psychiatric symptoms of dementia (BPSD) occur frequently, representing a significant driver of the total costs of dementia in the US. Although antidepressants and atypical antipsychotics are often used in BPSD, they have limited effectiveness and significant toxicity. As a result, recent initiatives have focused on reducing polypharmacy and psychotropic prescribing in this population. Combinatorial pharmacogenomic testing has demonstrated utility in guiding prescribing for psychotropic medications in patients with depression by identifying medications unlikely to be safe or effective due to significant gene-drug interactions.
Source: The American Journal of Geriatric Psychiatry - Category: Geriatrics Authors: Tags: Poster Number: NR-11 Source Type: research